Phase 3 clinical-stage biopharmaceutical company Scholar Rock (NASDAQ:SRRK) priced an upsized underwritten public offering of 12.41M shares at a public offering price of $6.85 per share.
The aggregate gross proceeds to Scholar Rock from this offering are expected to be ~$85M.
The offering is expected to close on October 16, 2023.
Underwriters have a 30-day option to purchase up to an additional 1.86M shares.
Net proceeds from the offering to advance apitegromab, develop its clinical and preclinical pipeline, as well as for working capital and other general corporate purposes.
